UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000010688
Receipt number R000012494
Scientific Title Random Phase II Study of Effectiveness of Laftidine and Pregabalin for Paclitacel-Induced Peripheral Neuropathy in the Patients with Gynecologic Malignancy
Date of disclosure of the study information 2013/07/15
Last modified on 2016/11/14 10:09:58

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Random Phase II Study of Effectiveness of Laftidine and Pregabalin for Paclitacel-Induced Peripheral Neuropathy in the Patients with Gynecologic Malignancy

Acronym

Random Phase II Study of Laftidine and Pregabalin for Paclitacel-Induced Peripheral Neuropathy

Scientific Title

Random Phase II Study of Effectiveness of Laftidine and Pregabalin for Paclitacel-Induced Peripheral Neuropathy in the Patients with Gynecologic Malignancy

Scientific Title:Acronym

Random Phase II Study of Laftidine and Pregabalin for Paclitacel-Induced Peripheral Neuropathy

Region

Japan


Condition

Condition

Paclitaxel-induced peripheral neuropathy in the patients with gynecological malignancies

Classification by specialty

Obstetrics and Gynecology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To access efficacy and safety of laftidine and pregabalin, respectively, for paclitaxel-induced peripheral neuropathy in the patients with gynecological malignancies

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

Response rate

Key secondary outcomes

Adverse event
Feasibility


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Administration of lafutidine (oral)

Interventions/Control_2

Administration of pregabalin (oral)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

1.Patients with gynecological malignancies (cancer in the ovary, peritoneum, tube, cervix, or endometrium) who have paclitaxel-induced peripheral neuropathy
2.Patients scheduled to receive the same regimen as a present regimen during at least 10 weeks
3.Patients obtained informed consent in a documented form

Key exclusion criteria

1.ECOG performance status: 3 or 4
2.Patients with neuropathy due to apparently other causes such as diabetes
3.Patients who have received more than two previous chemotherapy regimen
4.Patients with moderate to severe renal dysfunction (serum creatinine >1.5mg/ml, or creatinine clearance <30ml/min)
5.Patients with severe congestive heart failure
6.Patients with angioedema
7.Patients who have been administered laftidine or pregabalin previously for peripheral neuropathy
8.Patients taking any antidepressants or any anticonvulsants
9.Patients for whom completion of this study is deemed inappropriate for any reason

Target sample size

80


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hiroaki Nagano

Organization

Tokyo Women's Medical University, Medical Center East

Division name

Obstetrics and Gynecology

Zip code


Address

2-1-10, Nishiogu, Arakawa-ku

TEL

03-3810-1111

Email

naganoog@dnh.twmu.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hiroaki Nagano

Organization

Tokyo Women's Medical University, Medical Center East

Division name

Obstetrics and Gynecology

Zip code


Address

2-1-10, Nishiogu, Arakawa-ku

TEL

03-3810-1111

Homepage URL


Email

naganoog@dnh.twmu.ac.jp


Sponsor or person

Institute

Kansai Clinical Oncology Group

Institute

Department

Personal name



Funding Source

Organization

Kansai Clinical Oncology Group

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

YES

Study ID_1

KCOG-G1304

Org. issuing International ID_1

Kansai Clinical Oncology Group

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 07 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2013 Year 10 Month 02 Day

Date of IRB


Anticipated trial start date

2013 Year 11 Month 06 Day

Last follow-up date

2016 Year 10 Month 31 Day

Date of closure to data entry

2016 Year 10 Month 31 Day

Date trial data considered complete

2016 Year 10 Month 31 Day

Date analysis concluded

2016 Year 10 Month 31 Day


Other

Other related information



Management information

Registered date

2013 Year 05 Month 10 Day

Last modified on

2016 Year 11 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012494


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name